Yumanity’s Coles picks Merrimack, Onyx alum Peters to lead company to the clinic

As it gears up to enter the clinic next quarter, neurodegeneration company Yumanity hired Richard Peters as CEO to succeed Tony Coles, aiming to leverage Peters’ experience managing neurology trials into at least three clinical assets by 2021.

Peters plans to meet this goal without losing momentum on the company's foundational drug discovery activities, which generated at least eight neurodegeneration targets since the company's launch in 2014. ...